Hancock Mark sold $8.6M of PACS

Hancock Mark (Co Fndr; Exec V Chair) sold 236,320 shares of PACS Group, Inc. (PACS) at an average of $36.18 ($35.90–$37.88, $8.55M total) across 4 trades over 2026-06-15 to 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hancock Mark
Published Jun 17, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PACS
Bearish
medium confidence
Mentioned
$PACS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACSBearishLow
01

Why it matters

The disclosure provides a concrete, dated insider selling event (236,320 shares; ~$8.55M) but is mitigated by the stated use of a Rule 10b5-1 pre-arranged plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing alone is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The filing does not disclose reasons for sale, and the net effect depends on whether there are offsetting insider buys or other contemporaneous fundamental updates.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-17; trades executed 2026-06-15 to 2026-06-16.

Background

The article is an SEC EDGAR Form 4 insider transaction for PACS Group, Inc., reporting an open-market sale by an executive/director/10% owner.

Company-level read

Ticker impact

$PACSBearishMedium confidence
Context

PACS Group disclosed via SEC Form 4 that Hancock Mark (Exec V Chair, 10% owner) sold 236,320 shares for ~$8.55M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be small unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is primary-source and time-stamped, but it is an open-market sale executed under a pre-arranged 10b5-1 plan, which typically dampens inference about near-term fundamentals.

Market effects

No sector-wide read-through; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sales were executed under a pre-arranged 10b5-1 plan, the transaction may reflect liquidity/portfolio management rather than a bearish view.

Key entities

  • PACS Group, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Hancock Mark

    Exec V Chair; officer/director/10% owner who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PACSMedAI 8/10

What PACS Group (PACS) Said on Its Q3 Earnings Call

PACS Group reported 196 mature, 90 ramping, and 35 new skilled nursing facilities with occupancy ranging from 76.2% to 93.1%. The company acquired 32 Florida and 10 Texas skilled nursing operations post-quarter. PACS raised its 2026 revenue outlook to $5.95B-$6.05B and adjusted EBITDA to $685M-$695M, citing strength in existing operations and new acquisitions. Operating cash flow was $583.1M for the first nine months of 2026, with $707.4M in available liquidity.

$PACSHighAI 8/10

PACS Group Inc (PACS) (Q3 2026) Earnings Call Highlights: Revenue Tops

PACS Group Inc (NYSE:PACS) reported Q3 2026 revenue growth of 6.4%, with adjusted EBITDA up 33.6% to $175.7M. The company raised full-year guidance, citing strong occupancy and skilled mix improvements. PACS also highlighted a robust acquisition pipeline and integration plans for 31 Eduro facilities. Challenges include lower metrics at newly acquired facilities and ongoing government investigations.

$PACSHigh

Why is PACS stock surging today?

PACS Group Inc (PACS) stock rose 6.0% in after-hours trading after beating Q3 2026 earnings and revenue estimates. The company also raised its full-year 2026 Adjusted EBITDA and revenue guidance. Analysts maintain a 'Moderate Buy' rating with an average price target of $58.80. The surge was driven by company-specific news.